Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress

Mutagenesis

Volumn 31, Issue 5, 2016, Pages 573-582

  Garg, Bhavuk ^a   Pathria, Gaurav ^a,b   Wagner, Christine ^a   Maurer, Margarita ^a   Wagner, Stephan N ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SIGNAL PEPTIDE; SIGNAL SEQUENCE RECEPTOR 2; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; CALCIUM BINDING PROTEIN; CELL RECEPTOR; MEMBRANE PROTEIN; RECEPTOR; SIGNAL SEQUENCE RECEPTOR;

ARTICLE; CANCER PATIENT; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM MEMBRANE; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; ONCOGENE; PRIORITY JOURNAL; SSR2 GENE; TRANSCRIPTION REGULATION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; PATHOPHYSIOLOGY; TRANSCRIPTION INITIATION;

CALCIUM-BINDING PROTEINS; CELL LINE; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, PEPTIDE; TRANSCRIPTIONAL ACTIVATION; UNFOLDED PROTEIN RESPONSE;

EID: 84985993324     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gew023     Document Type: Article

References (66)

1. Garraway, L. A., and Lander, E. S. (2013) Lessons from the cancer genome. Cell, 153, 17-37.
2. Larkin, J., Ascierto, P. A., Dréno, B., et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 371, 1867-1876.
3. Long, G. V., Stroyakovskiy, D., Gogas, H., et al. (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med., 371, 1877-1888.
4. Hodi, F. S., Corless, C. L., Giobbie-Hurder, A., et al. (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol., 31, 3182-3190.
5. Kwong, L. N., Costello, J. C., Liu, H., et al. (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med., 18, 1503-1510.
6. Jalili, A., Wagner, C., Pashenkov, M., et al. (2012) Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J. Natl. Cancer Inst., 104, 1673-1679.
7. Sosman J.A., Kittaneh, M., Lolkema, M., et al. (2014) A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. J Clin Oncol, suppl; abstr 9009
8. Miller, D.M., Flaherty, K.T., and Tsao, H. (2014) Commentary: Molecular testing in melanoma. J Am Acad Dermatol., 70, 863-870.
9. Romano, E., Schwartz, G. K., Chapman, P. B., Wolchock, J. D., and Carvajal, R. D. (2011) Treatment implications of the emerging molecular classification system for melanoma. Lancet. Oncol., 12, 913-922.
10. Krauthammer, M., Kong, Y., Bacchiocchi, A., et al. (2015) Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sunexposed melanomas. Nat. Genet., 47, 996-1002.
11. The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell, 161, 1681-1696.
12. Hodis, E., Watson, I. R., Kryukov, G. V., et al. (2012) A landscape of driver mutations in melanoma. Cell, 150, 251-263.
13. Schadendorf D., Fisher, D.E., Garbe, C., et al. (2015) Melanoma. Nat Rev Dis Primers, 15003
14. Kaminker, J. S., Zhang, Y., Watanabe, C., and Zhang, Z. (2007) CanPredict: a computational tool for predicting cancer-Associated missense mutations. Nucleic Acids Res., 35, W595-W598.
15. Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., and Karchin, R. (2009) Cancer-specific high-Throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res., 69, 6660-6667.
16. Meyerson, M., Gabriel, S., and Getz, G. (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genetics, 11, 685-696.
17. Youn, A., and Simon, R. (2011) Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics, 27, 175-181.
18. Mertz, K. D., Pathria, G., Wagner, C., et al. (2014) MTSS1 is a metastasis driver in a subset of human melanomas. Nat. Commun., 5, 3465.
19. Berger, M. F., Hodis, E., Heffernan, T. P., et al. (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 485, 502-506.
20. Curtin, J. A., Fridlyand, J., Kageshita, T., et al. (2005) Distinct sets of genetic alterations in melanoma. N. Engl. J. Med., 353, 2135-2147.
21. Krauthammer, M., Kong, Y., Ha, B. H., et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet., 44, 1006-1014.
22. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463, 191-196.
23. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., et al.; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. (2013) Signatures of mutational processes in human cancer. Nature, 500, 415-421.
24. Kabbarah, O., Nogueira, C., Feng, B., et al. (2010) Integrative genome comparison of primary and metastatic melanomas. PLoS One, 5, e10770.
25. Eccles, S. A., Box, C., and Court, W. (2005) Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol. Annu. Rev., 11, 391-421.
26. Xu, L., Shen, S. S., Hoshida, Y., et al. (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol. Cancer Res., 6, 760-769.
27. Jalili, A., Mertz, K. D., Romanov, J., et al. (2013) NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One, 8, e69064.
28. Jalili, A., Moser, A., Pashenkov, M., et al. (2011) Polo-like kinase 1 is a potential therapeutic target in human melanoma. J. Invest. Dermatol., 131, 1886-1895.
29. Calzada-Wack, J., Kappler, R., Schnitzbauer, U., Richter, T., Nathrath, M., Rosemann, M., Wagner, S. N., Hein, R., and Hahn, H. (2002) Unbalanced overexpression of the mutant allele in murine Patched mutants. Carcinogenesis, 23, 727-733.
30. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
31. Cerami, E., Gao, J., Dogrusoz, U., et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov., 2, 401-404.
32. Ménétret, J. F., Hegde, R. S., Heinrich, S. U., Chandramouli, P., Ludtke, S. J., Rapoport, T. A., and Akey, C. W. (2005) Architecture of the ribosomechannel complex derived from native membranes. J. Mol. Biol., 348, 445-457.
33. Ménétret, J. F., Hegde, R. S., Aguiar, M., Gygi, S. P., Park, E., Rapoport, T. A., and Akey, C. W. (2008) Single copies of Sec61 and TRAP associate with a nontranslating mammalian ribosome. Structure, 16, 1126-1137.
34. Fons, R. D., Bogert, B. A., and Hegde, R. S. (2003) Substrate-specific function of the translocon-Associated protein complex during translocation across the ER membrane. J. Cell Biol., 160, 529-539.
35. Chung, B. D., Kayserili, H., Ai, M., et al. (2009) A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Hum. Mutat., 30, 641-648.
36. Datta, R., Waheed, A., Shah, G. N., and Sly, W. S. (2007) Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl. Acad. Sci. USA, 104, 19989-19994.
37. Rebello, G., Ramesar, R., Vorster, A., et al. (2004) Apoptosis-inducing signal sequence mutation in carbonic anhydrase IV identified in patients with the RP17 form of retinitis pigmentosa. Proc. Natl. Acad. Sci. USA, 101, 6617-6622.
38. Allison, D. S., and Young, E. T. (1989) Mutations in the signal sequence of prepro-Alpha-factor inhibit both translocation into the endoplasmic reticulum and processing by signal peptidase in yeast cells. Mol. Cell. Biol., 9, 4977-4985.
39. Pieniek, A., Czepas, J., Piasecka-Zelga, J., Gwodziski, K., and Koceva-Chya, A. (2013) Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Adv. Med. Sci., 58, 104-111.
40. Deavall, D. G., Martin, E. A., Horner, J. M., and Roberts, R. (2012) Druginduced oxidative stress and toxicity. J. Toxicol., 2012, 645460.
41. Ma, X. H., Piao, S. F., Dey, S., et al. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Invest., 124, 1406-1417.
42. Hetz, C., Chevet, E., and Harding, H. P. (2013) Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov., 12, 703-719.
43. Romero-Ramirez, L., Cao, H., Nelson, D., et al. (2004) XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res., 64, 5943-5947.
44. Chen, X., Iliopoulos, D., Zhang, Q., et al. (2014) XBP1 promotes triple-negative breast cancer by controlling the HIF1' pathway. Nature, 508, 103-107.
45. Helms, J. B., and Rothman, J. E. (1992) Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature, 360, 352-354.
46. Patil, C., and Walter, P. (2001) Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr. Opin. Cell Biol., 13, 349-355.
47. Garraway, L. A., Widlund, H. R., Rubin, M. A., et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436, 117-122.
48. Acosta-Alvear, D., Zhou, Y., Blais, A., Tsikitis, M., Lents, N. H., Arias, C., Lennon, C. J., Kluger, Y., and Dynlacht, B. D. (2007) XBP1 controls diverse cell type-And condition-specific transcriptional regulatory networks. Mol. Cell, 27, 53-66.
49. Oslowski, C. M., and Urano, F. (2011) Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol., 490, 71-92.
50. Rapoport, T. A. (2007) Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature, 450, 663-669.
51. Sommer, N., Junne, T., Kalies, K. U., Spiess, M., and Hartmann, E. (2013) TRAP assists membrane protein topogenesis at the mammalian ER membrane. Biochim. Biophys. Acta, 1833, 3104-3111.
52. Nyathi, Y., Wilkinson, B. M., and Pool, M. R. (2013) Co-Translational targeting and translocation of proteins to the endoplasmic reticulum. Biochim. Biophys. Acta, 1833, 2392-2402.
53. Kalies, K. U., Rapoport, T. A., and Hartmann, E. (1998) The beta subunit of the Sec61 complex facilitates cotranslational protein transport and interacts with the signal peptidase during translocation. J. Cell Biol., 141, 887-894.
54. Mesbah, K., Camus, A., Babinet, C., and Barra, J. (2006) Mutation in the Trapalpha/Ssr1 gene, encoding translocon-Associated protein alpha, results in outflow tract morphogenetic defects. Mol. Cell. Biol., 26, 7760-7771.
55. Yamaguchi, Y. L., Tanaka, S. S., Oshima, N., Kiyonari, H., Asashima, M., and Nishinakamura, R. (2011) Translocon-Associated protein subunit Trap-'/Ssr3 is required for vascular network formation in the mouse placenta. Dev. Dyn., 240, 394-403.
56. Mangos, S., Krawetz, R., and Kelly, G. M. (2000) The Translocon-Associated Protein beta (TRAPbeta) in zebrafish embryogenesis. I. Enhanced expression of transcripts in notochord and hatching gland precursors. Mol. Cell. Biochem., 215, 93-101.
57. Croft, A., Tay, K. H., Boyd, S. C., et al. (2014) Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J. Invest. Dermatol., 134, 488-497.
58. Corazzari, M., Rapino, F., Ciccosanti, F., Giglio, P., Antonioli, M., Conti, B., Fimia, G. M., Lovat, P. E., and Piacentini, M. (2015) Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ., 22, 946-958.
59. Luo, B., and Lee, A. S. (2013) The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene, 32, 805-818.
60. Beck, D., Niessner, H., Smalley, K. S., et al. (2013) Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci. Signal., 6, ra7.
61. Chevet, E., Hetz, C., and Samali, A. (2015) Endoplasmic reticulum stress-Activated cell reprogramming in oncogenesis. Cancer Discov., 5, 586-597.
62. Clarke, H. J., Chambers, J. E., Liniker, E., and Marciniak, S. J. (2014) Endoplasmic reticulum stress in malignancy. Cancer Cell, 25, 563-573.
63. Hetz, C. (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol., 13, 89-102.
64. Nagasawa, K., Higashi, T., Hosokawa, N., Kaufman, R. J., and Nagata, K. (2007) Simultaneous induction of the four subunits of the TRAP complex by ER stress accelerates ER degradation. EMBO Rep., 8, 483-489.
65. DuRose, J. B., Tam, A. B., and Niwa, M. (2006) Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress. Mol. Biol. Cell, 17, 3095-3107.
66. Li, B., Yi, P., Zhang, B., Xu, C., Liu, Q., Pi, Z., Xu, X., Chevet, E., and Liu, J. (2011) Differences in endoplasmic reticulum stress signalling kinetics determine cell survival outcome through activation of MKP-1. Cell. Signal., 23, 35-45.